CLINICAL_TRIALS
trial_result
· 2018-04-23
Clinical Trial Update: Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS) [Phase 2]
Summary
Phase 2 trial update for pacritinib in lower-risk myelodysplastic syndromes has been terminated with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: M.D. Anderson Cancer Center | Conditions: Leukemia | Phase 2 | Status: TERMINATED | Results posted: 2018-04-23